11:19 PM EST, 11/05/2026 (MT Newswires) -- Medacta Group (MOVE.SW) adjusted its full-year 2026 revenue guidance while confirming its midterm outlook, according to a Thursday release. The Swiss orthopedic products company now expects revenue growth of 9% in constant currency, against the previous forecast of 10% to 14%. Meanwhile, Medacta reiterated its 2024-2027 midterm guidance of a revenue compound annual growth rate of 12% to 15% in constant currency.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.